News | News By Subject | News by Disease News By Date | Search News

Respiratory syncytial virus News Articles

Get Our FREE
Industry eNewsletter
email:    
Top Breaking News
Aviragen Delays Further Enrollment in Phase IIa Trial of BTA585     5/27/2016
Mymetics Announces Discontinuation of the RSV Collaborative Project     1/29/2016
Novavax (NVAX) Snags Grant Worth $89 Million from Bill & Melinda Gates Foundation     9/29/2015
Novavax (NVAX)'s RSV Vaccine Protect Infants via Maternal Immunization in Phase II Study     9/29/2015
Bay Area's Raptor (RPTP) Beefs Up Portfolio With $453 Million Deal for Quinsair     8/21/2015
Analyst: Current Crop of Biotech IPOs a Mixed Bag of Low Market Caps, Little Data     12/3/2014
Best Value In Biotech? Actavis (ACT), Says UBS     11/17/2014
Gilead Sciences, Inc. (GILD)'s Respiratory Syncytial Virus (RSV) Drug GS-5806 Wows In Phase 2 Trial     5/27/2014
AstraZeneca PLC (AZN) Touts Success In 2 Phase 2 Studies     5/15/2014
Novavax, Inc. (NVAX) Vaccine Meets Mid-Stage Trial Goal     4/4/2013
FDA Staff Flag Reaction Risk With AstraZeneca PLC (AZN)'s RSV Drug Motavizumab     5/28/2010
Alnylam Pharmaceuticals (ALNY) and Cubist Pharmaceuticals, Inc. (CBST) (JOBS) Announce Complete Data From Phase II Study Of ALN-RSV01 In Lung Transplant Patients Infected With Respiratory Syncytial Virus; Lung Drug Meets Main Goal     7/20/2009
Pharmacopeia, Inc. (PCOP) Receives Milestone Payment from GlaxoSmithKline (GSK) as a Result of Lead Compound Identification     6/4/2008
Alnylam Pharmaceuticals (ALNY) Drug Effective Against RSV Infection     2/29/2008
MedImmune, Inc.'s Motavizumab Reduced RSV Hospitalizations by 83 Percent Among High-Risk Native American, Full-Term Infants in Placebo-Controlled Phase 3 Study - Primary Endpoint Met     8/23/2007

News from Around the Web
Ginseng Can Treat And Prevent Influenza, Georgia State University Study     4/22/2014
Vitamin D May Prevent Serious Respiratory Disease in Newborns, University Medical Center and Collaborators Study     5/10/2011
Drug for RSV Linked to Shorter Hospital Stays, Albert Einstein College of Medicine Study     5/3/2010
Risk Factors For Severe RSV Infection In Immunocompromised Children Identified, St. Jude Children's Research Hospital Study     2/8/2008
New Treatment Approach Holds Promise For Children Infected By Dangerous Respiratory Virus     10/17/2006
RSV A Significant Risk In Elderly And High-risk Adults     4/27/2005
Legionnaire's Germ Yields Genetic Code     9/24/2004
Researchers Discover Cold Virus Can "Hit And Hide"     4/26/2004
Aventis: 5 Japanese Die After Taking Drug     1/28/2004

Press Releases
ReViral Initiates Phase 1 Clinical Trial Of Potent Oral Inhibitor Against Respiratory Syncytial Virus     10/31/2016
AstraZeneca PLC (AZN) Release: New Data Shows Frequent ICU Admissions From Severe RSV Disease Among Preterm Infants In The First Three Months Of Life     10/28/2016
Aviragen Resumes Enrollment In Phase IIa RSV Challenge Trial     7/12/2016
Vaxart Initiates Clinical Development Of First Oral RSV Vaccine     6/28/2016
Novavax (NVAX) Announces New Seasonal Combination Respiratory Vaccine Program     6/3/2016
FDA Grants Fast Track Designation To Novavax (NVAX)’ RSV F Vaccine For Older Adults     5/25/2016
Ablynx (ABLYF) Reports Positive Top Line Results For Its Anti-RSV Nanobody (ALX-0171) Inhaled Using Vectura (VEC.L)’s FOX Device In A Phase I/IIa Study In Infants Hospitalized With RSV Infection     5/3/2016
Mucosis B.V. Secures €3.7M From Wellcome Trust To Fund Clinical Trials Of Its Respiratory Syncytial Virus Vaccine In Partnership With Imperial College London     1/19/2016
Novavax (NVAX) Completes Enrollment Of Pivotal Phase III Trial Of The RSV F Vaccine In Older Adults     12/15/2015
Novavax (NVAX) Initiates Global Pivotal Phase III Trial Of The RSV F Vaccine To Protect Infants Via Maternal Immunization     12/4/2015
DBV Tech To Present Preclinical Data On Its Viaskin Technology For RSV Vaccination At The 2015 RSV Vaccines For The World Meeting     11/18/2015
Novavax (NVAX) To Make Multiple Presentations At RSV Vaccines For The World     11/17/2015
Novavax (NVAX) Initiates Pivotal Phase III Trial Of The RSV F Vaccine In Older Adults     11/9/2015
VBI Vaccines To Present Update And New Data Supporting Its RSV And CMV Vaccine Programs At The World Vaccine Congress Europe     11/6/2015
MEDI7510 For Respiratory Syncytial Virus Advances To Phase II Leverages Immune Design Corporation (IMDZ)'s GLAAS(TM) Discovery Platform     10/29/2015

//-->